首页> 外文OA文献 >PCN206 - ANAPLASTIC LYMPHOMA KINASE (ALK) TESTING IN NON-SMALL CELL LUNG CARCINOMA (NSCLC): RECOMMENDED TESTS AND COVERAGE POLICIES ACROSS ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT (OECD) COUNTRIES

【2h】

PCN206 - ANAPLASTIC LYMPHOMA KINASE (ALK) TESTING IN NON-SMALL CELL LUNG CARCINOMA (NSCLC): RECOMMENDED TESTS AND COVERAGE POLICIES ACROSS ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT (OECD) COUNTRIES

机译：PCN206 - 非小细胞肺癌（NSCLC）中的促进淋巴瘤激酶（ALK）测试：跨经济合作和发展（经合组织）国家的建议试验和覆盖政策

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
J. Kumar; R. Patel; P. Aggarwal; B.N. Adler; J. Gupta;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): Results of a multi-centre ALK-testing [J] . v.LaffertM., WarthA., PenzelR., Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2013,第2期

机译：非小细胞肺癌（NSCLC）的间变性淋巴瘤激酶（ALK）基因重排：多中心ALK测试的结果
2. Clinical implications and future perspectives in testing non-small cell lung cancer (NSCLC) for anaplastic lymphoma kinase ( ALK ) gene rearrangements [J] . Francesco Gelsomino, Giulio Rossi, Marcello Tiseo Journal of Thoracic Disease . 2015,第3期

机译：检测非小细胞肺癌（NSCLC）间变性淋巴瘤激酶（ALK）基因重排的临床意义和未来展望
3. Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1 [J] . Kim D., Mehra R., Tan D. S. W., International Journal of Radiation Oncology, Biology, Physics . 2014,第5Suppla期

机译：Ceritinib在晚期间变性再生性淋巴瘤激酶（ALK）重排（ALK plus）非小细胞肺癌（NSCLC）患者中的疗效和安全性：ASCEND-1的更新
4. Development of Renewable RNA Reference Standards for Non-Small Cell Lung Carcinoma (NSCLC) Diagnostics [C] . Andrea DAmbroggio, M. Hou, F. Patell-Socha, International Molecular Medicine Tri-Conference. . 2016

机译：非小细胞肺癌（NSCLC）诊断可再生RNA参考标准的开发
5. Clinical implications and future perspectives in testing non-small cell lung cancer (NSCLC) for anaplastic lymphoma kinase (ALK) gene rearrangements [O] . Francesco Gelsomino, Giulio Rossi, Marcello Tiseo 2015

机译：非小细胞肺癌（NSCLC）检测间变性淋巴瘤激酶（ALK）基因重排的临床意义和未来展望
6. Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC) [O] . Reckamp Karen L., Infante Jeffrey R., Blumenschein George R., 2016

机译：X-396（一种新型的间变性淋巴瘤激酶（ALK）抑制剂）在ALK +非小细胞肺癌（NSCLC）患者中的I / II期试验

PCN206 - ANAPLASTIC LYMPHOMA KINASE (ALK) TESTING IN NON-SMALL CELL LUNG CARCINOMA (NSCLC): RECOMMENDED TESTS AND COVERAGE POLICIES ACROSS ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT (OECD) COUNTRIES

著录项

引文网络

相似文献

相关主题

期刊订阅